[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chidamide\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chidamide":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100603226","phase-1-application-of-pd-1-inhibitors-tenofovir-chidamide-and-lenalidomide-in-relapsedrefractory-ebv-associated-lymphoproliferative-disorders-100603226",false,"NCT07133763","Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed\u002FRefractory EBV-associated Lymphoproliferative Disorders.","A Multicenter, Single-Arm, Prospective Study to Evaluate the Efficacy and Safety of PD-1 Inhibitor Combined With Tenofovir, Chidamide, and Lenalidomide in the Treatment of Relapsed or Refractory EBV-Associated Lymphoproliferative Disorders.","Inclusion Criteria:\n\n1. Histologically confirmed EBV-associated lymphoproliferative disorders, including EBV-positive B-cell LPD and EBV-positive T\u002FNK-cell LPD, with EBV-encoded RNA (EBER)+ by in situ hybridization, or EBV nuclear antigen (EBNA)+, or latent membrane protein (LMP1\u002F2)+ in the lesion tissue.\n2. Age ≤75 years with an ECOG performance status ≤2.\n3. At least one bidimensionally measurable lesion for evaluation: for nodal lesions, longest diameter ≥1.5 cm and shortest diameter ≥1.0 cm; for extranodal lesions, longest diameter ≥1.0 cm; or ≥20% monoclonal EBV-infected lymphocytes detected by flow cytometry.\n4. Expected survival of more than 3 months.\n5. Ability to comply with follow-up. Patients must be aware of the nature of their disease and voluntarily agree to participate in the study and follow-up.\n\nExclusion Criteria:\n\n1. Patients with impaired liver or kidney function, defined as serum direct bilirubin, indirect bilirubin, and\u002For ALT, AST, or serum creatinine levels \\>2 times the upper limit of normal, unless deemed lymphoma-related.\n2. Patients with bone marrow failure, defined as absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL or platelets \\\u003C75×10⁹\u002FL, unless the hematologic abnormalities are considered due to bone marrow infiltration by lymphoma.\n3. Patients who have experienced grade ≥3 neurotoxicity within the past 2 weeks.\n4. Patients with chronic heart failure classified as NYHA Class III or IV, or with left ventricular ejection fraction \\\u003C50%, or with a history within the past 6 months of any of the following: acute coronary syndrome, acute heart failure (Class III or IV), or significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, or post-resuscitation sudden cardiac arrest).\n5. Patients with AIDS, syphilis, or active hepatitis B (HBV DNA \\>1×10⁴ copies\u002Fml) or active hepatitis C infection.\n6. Patients diagnosed with malignancies other than lymphoma or currently undergoing treatment for other cancers, except:\n\n   ① Those who have received curative treatment and have been disease-free for ≥5 years prior to enrollment;\n\n   ② Patients with adequately treated, non-melanoma skin cancers such as basal cell carcinoma without evidence of disease;\n\n   ③ Patients with adequately treated carcinoma in situ of the cervix without evidence of disease.\n7. Patients with other hematologic diseases (e.g., hemophilia, myelofibrosis) considered unsuitable for the study by the investigator.\n8. Patients with severe active infections.\n9. Patients who underwent Grade 2 or higher surgery within 3 weeks before treatment initiation.\n10. Patients with a history of substance abuse, or medical, psychological, or social conditions that may interfere with study participation or evaluation, as judged by the investigator.\n11. Any other condition the investigator considers unsuitable for study enrollment.\n12. Known hypersensitivity to any component of the investigational drugs.","ALL","0 Years","75 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study is a prospective, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of PD-1 inhibitor combined with tenofovir, chidamide, and lenalidomide in the treatment of relapsed or refractory Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs). The primary endpoint is the overall response rate (ORR) at 3 months, including complete response (CR) and partial response (PR). Secondary endpoints include overall survival (OS), progression-free survival (PFS), as well as safety and tolerability assessments. Eligible patients must have histologically confirmed EBV-positive B-cell or T\u002FNK-cell LPDs with measurable lesions. This combination regimen targets multiple mechanisms, including inhibition of EBV replication, activation of the immune system, and enhancement of antitumor effects, aiming to provide an innovative therapeutic strategy for this challenging disease.",[28,29,30,31,32],"EBV-Associated Lymphoproliferative Disorders","PD-1 Inhibitor","Tenofovir","Chidamide","Lenalidomide",[28,29,34,31,35],"tenofovir","lenalidomide","NOT_YET_RECRUITING","2025-08-14",{"date":39,"type":40},"2025-08-21","ACTUAL",{"date":42,"type":21},"2025-09-01",{"date":44,"type":21},"2027-09-01",{"name":46,"class":47},"The Affiliated Hospital of Xuzhou Medical University","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":66,"locationsCount":4},"100603227","phase-1-application-of-pd-1-inhibitors-combined-with-tenofovir-chidamide-and-lenalidomide-in-the-treatment-of-ebv-associated-diseases-100603227","NCT07133776","Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.","A Multicenter, Single-Arm, Prospective Clinical Study to Evaluate the Efficacy and Safety of PD-1 Inhibitor Combined With Tenofovir, Chidamide, and Lenalidomide in the Treatment of EBV-Associated Diseases","Inclusion Criteria:\n\n1. Diagnosed with EBV infectious diseases, including infectious mononucleosis, chronic active EBV infection, or other EBV infectious diseases;\n2. EBV DNA ≥ 10⁴ copies\u002FmL in whole blood or plasma;\n3. Age ≤ 75 years with ECOG performance status ≤ 2;\n4. Estimated life expectancy over 3 months;\n5. Patients must be able to undergo follow-up. They should understand the nature of their disease and voluntarily agree to participate in this study for treatment and follow-up.\n\nExclusion Criteria:\n\n1. Patients with impaired liver or kidney function, specifically defined as serum direct bilirubin, indirect bilirubin, and\u002For ALT, AST, or serum creatinine \\>2 times the upper limit of normal (ULN), unless such abnormalities are attributed to lymphoma;\n2. Patients with bone marrow failure, defined as absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL or platelets \\\u003C75×10⁹\u002FL;\n3. Patients who have experienced grade III or higher neurotoxicity within the past 2 weeks;\n4. Patients with chronic heart failure classified as NYHA class III or IV, or left ventricular ejection fraction (LVEF) \\\u003C50%, or those with a history of the following cardiac events within the past 6 months: acute coronary syndrome, acute heart failure (NYHA class III or IV), or significant ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, or resuscitated sudden cardiac arrest);\n5. Patients with AIDS, syphilis, or active hepatitis B (HBV DNA \\>1×10⁴ copies\u002FmL) or hepatitis C infection;\n6. Patients with coexisting hematologic disorders (e.g., hemophilia, myelofibrosis) deemed unsuitable for inclusion by the investigator;\n7. Patients with severe concurrent infections;\n8. Patients who have undergone grade II or higher surgery within 3 weeks prior to treatment;\n9. Patients with substance abuse, medical, psychological, or social conditions that may interfere with study participation or the evaluation of study outcomes;\n10. Patients deemed unsuitable for enrollment by the investigator;\n11. Patients with known hypersensitivity to components of the investigational drug.",{"count":56,"type":21},30,[24,25],"Currently, treatment options for Epstein-Barr virus (EBV) infection are limited, with unsatisfactory efficacy and no established standard therapy. Therefore, our center is conducting a prospective, multicenter, single-arm clinical trial to evaluate the efficacy and safety of PD-1 inhibitor in combination with tenofovir, chidamide, and lenalidomide in patients with EBV infectious diseases, aiming to provide a more effective and safer therapeutic option for EBV infectious diseases.",[60,29,30,31,32],"Epstein-Barr Virus (EBV) Infection",[62,29,34,31,35],"Epstein-Barr Virus (EBV) infection",{"date":39,"type":40},{"date":42,"type":21},{"date":44,"type":21},{"name":46,"class":47},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100584577","phase-2-chidamide-plus-r-chop-in-newly-diagnosed-double-expressor-diffuse-large-b-cell-lymphoma-with-other-molecular-subtypes-100584577","NCT06891157","Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes","Chidamide Plus R-CHOP (CR-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes: A Prospective, Multicenter Phase II Trial","Inclusion Criteria:\n\n* Patients must meet all of the following inclusion criteria to be eligible for enrollment:\n\n  1. ≥18 years of age;\n  2. Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;\n  3. Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the \"Other\" subtype;\n  4. Immunohistochemistry revealed overexpression of MYC and BCL2: MYC ≥ 40%, BCL2 ≥ 50%;\n  5. Measurable lesions identified on cross-sectional imaging through diagnostic modalities (computed tomography \\[CT\\] or magnetic resonance imaging \\[MRI\\]) are defined as the presence of at least one two-dimensional lesion with a maximum cross-sectional diameter (GTD) ≥1.5 cm, irrespective of the short-axis diameter;\n  6. The Eastern Cooperative Oncology Group (ECOG) performance status score is ≤2；\n  7. Adequate hepatic function is defined as: total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN; alkaline phosphatase (ALP) ≤ 5 × ULN; serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 35 mL\u002Fmin as calculated by the Cockcroft-Gault formula;\n  8. Voluntary participation with willingness to provide the aforementioned treatment data, accompanied by a signed and dated informed consent form.\n\n     Exclusion Criteria:\n* Patients who meet any of the following criteria will be excluded from the study：\n\n  1. Currently enrolled in another clinical trial；\n  2. Received prior lymphoma treatment with alternative regimens before enrollment;\n  3. Presence of concurrent malignant tumors;\n  4. Deemed ineligible for participation by the investigator's judgment；\n  5. Presence of severe psychiatric or neurological disorders that may impair the ability to provide informed consent and\u002For affect the reporting or observation of adverse events；\n  6. Patients unable to comply with follow-up requirements；\n  7. Pregnant or lactating women, and patients of childbearing potential unwilling to use contraception;\n  8. Active infection or uncontrolled HBV (HBsAg positive and\u002For HBcAb positive and HBV DNA positive), HCV positive","18 Years",{"count":76,"type":21},148,[25],"Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes",[31,80,81,82],"R-CHOP Chemotherapy","DLBCL - Diffuse Large B Cell Lymphoma","Double-expressor Lymphoma (DEL)","RECRUITING","2025-03-20",{"date":86,"type":40},"2025-03-24",{"date":88,"type":40},"2024-08-20",{"date":90,"type":21},"2027-08-20",{"name":92,"class":47},"The First Affiliated Hospital with Nanjing Medical University",1]